Dosing & Uses
Dosage Forms & Strengths
- 0.3mg/90mcL (prefilled syringe)
Neovascular (Wet) Age-Related Macular Degeneration
0.3 mg intravitreous q6Weeks
Indication not applicable to children
Anterior chamber inflammation
Eye discharge, irritation, pain
Reduced visual acuity
Corneal abrasion, corneal deposits, corneal epithelial d/o
Eye inflammation/swelling, eyelid irritation
Vitreous d/o, vitreous hemorrhage
Carotid artery occlusion
Chest pain, contusion
Iatrogenic traumatic cataract
Use proper aseptic techniques to minimize risk of endophthalmitis
Risk of increased IOP; monitor IOP and perfusion of the optic nerve
In clinical studies, less effective in the second year than during the first
Efficacy decreased at doses >1 mg
Thromboembolic events reported following intravitreal administration of other VEGF inhibitors
Safety and efficacy of concurrent administration on both eyes not studied
Pregnancy & Lactation
Pregnancy Category: B
No adequate human data; in mice, produced no maternal toxicity and no evidence of teratogenicity or fetal mortality at IV doses up to 40 mg/kg/day (about 7,000 times the recommended human monocular ophthalmic dose of 0.3 mg/eye)
Lactation: Ecretion in breast milk unknown; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Aptamer that binds to and inhibits binding of the angiogenic cytokine VEGF to the receptor, which in turn suppresses neovascularization and slows vision loss
Endo- and exonucleases (based on preclinical data)
Excretion: Primarily urine
Half-life: 6-14 days
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs